 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- | DS-3078 / Daiichi Sankyo
Journal, IO Biomarker: Small molecule CDS-3078 induces G/M phase arrest and mitochondria-mediated apoptosis in HeLa cells. (Pubmed Central) - Nov 21, 2020
Therefore, CDS-3078 administration induced apoptosis via p53-mediated cell cycle arrest, causing mitochondrial dysfunction and resulting in apoptotic cell death in cervical cancer cells. Collectively, the present results suggested that CDS-3078 may be a potential anticancer agent.
- | DS-3078 / Daiichi Sankyo
Trial completion, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Apr 3, 2015
P1, N=32, Completed, Sponsor: Daiichi Sankyo Inc.
Collectively, the present results suggested that CDS-3078 may be a potential anticancer agent. Active, not recruiting --> Completed
- DS-3078 / Daiichi Sankyo
Trial primary completion date, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - May 19, 2014
P1, N=32, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Jun 2014
- DS-3078 / Daiichi Sankyo
Trial completion date, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - May 19, 2014
P1, N=32, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Trial primary completion date: Apr 2015 --> Jun 2014 Trial completion date: Apr 2015 --> Jun 2014
- DS-3078 / Daiichi Sankyo
Enrollment change, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - May 19, 2014
P1, N=32, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Trial completion date: Apr 2015 --> Jun 2014 N=46 --> 32
- DS-3078 / Daiichi Sankyo
Enrollment closed, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - May 19, 2014
P1, N=32, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
N=46 --> 32 Recruiting --> Active, not recruiting
- | DS-3078 / Daiichi Sankyo
New P1 trial, Metastases: A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Apr 29, 2012
P1, N=46, Recruiting, Sponsor: Daiichi Sankyo Inc.